CLRB Key Statistics, Chart & Performance
The current stock price of CLRB is 3.45 USD. In the past month the price increased by 2.99%. In the past year, price decreased by -92.53%.
CLRB Latest News, Press Relases and Analysis
CLRB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.09 | 402.18B | ||
| AMGN | AMGEN INC | 15.76 | 185.50B | ||
| GILD | GILEAD SCIENCES INC | 15.57 | 158.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.89 | 110.80B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.43 | 83.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 872.78 | 58.35B | ||
| INSM | INSMED INC | N/A | 43.23B | ||
| NTRA | NATERA INC | N/A | 32.54B | ||
| BIIB | BIOGEN INC | 10.87 | 26.67B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.51 | 22.09B | ||
| INCY | INCYTE CORP | 16.46 | 20.63B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.21B |
Related stock screener links
About CLRB
Company Profile
Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. The company is headquartered in Florham Park, New Jersey and currently employs 11 full-time employees. The company went IPO on 2005-05-20. The firm is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.
Company Info
CELLECTAR BIOSCIENCES INC
100 Campus Drive
Florham Park NEW JERSEY 07932 US
CEO: JamesV.Caruso
Employees: 11
Phone: 16084418120
CELLECTAR BIOSCIENCES INC / CLRB FAQ
Can you describe the business of CELLECTAR BIOSCIENCES INC?
Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. The company is headquartered in Florham Park, New Jersey and currently employs 11 full-time employees. The company went IPO on 2005-05-20. The firm is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.
Can you provide the latest stock price for CELLECTAR BIOSCIENCES INC?
The current stock price of CLRB is 3.45 USD. The price increased by 12.38% in the last trading session.
What is the dividend status of CELLECTAR BIOSCIENCES INC?
CLRB does not pay a dividend.
How is the ChartMill rating for CELLECTAR BIOSCIENCES INC?
CLRB has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the PE ratio for CLRB stock?
CELLECTAR BIOSCIENCES INC (CLRB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-10.8).
Can you provide the upcoming earnings date for CELLECTAR BIOSCIENCES INC?
CELLECTAR BIOSCIENCES INC (CLRB) will report earnings on 2026-03-11, after the market close.
CLRB Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CLRB. When comparing the yearly performance of all stocks, CLRB is a bad performer in the overall market: 97.42% of all stocks are doing better.
CLRB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CLRB. The financial health of CLRB is average, but there are quite some concerns on its profitability.
CLRB Financial Highlights
Over the last trailing twelve months CLRB reported a non-GAAP Earnings per Share(EPS) of -10.8. The EPS increased by 24.21% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -212.28% | ||
| ROE | -389.34% | ||
| Debt/Equity | 0 |
CLRB Forecast & Estimates
10 analysts have analysed CLRB and the average price target is 85.68 USD. This implies a price increase of 2383.48% is expected in the next year compared to the current price of 3.45.